Suppr超能文献

《危重症合并肾脏替代治疗患者抗菌药物剂量调整指南》

A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy.

机构信息

UO Dialisi, Azienda Ospedaliero-Universitaria Policlinico Umberto I, "Sapienza" Università di Roma, Rome, Italy.

UO Dialisi, Azienda Ospedaliero-Universitaria Policlinico Umberto I, "Sapienza" Università di Roma, Rome, Italy

出版信息

Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00583-19. Print 2019 Aug.

Abstract

A careful management of antimicrobials is essential in the critically ill with acute kidney injury, especially if renal replacement therapy is required. Acute kidney injury may lead to clinically significant modifications of drugs' pharmacokinetic parameters, and the need for renal replacement therapy represents a further variable that should be considered to avoid inappropriate antimicrobial therapy. The most important pharmacokinetic parameters, useful to determine the significance of extracorporeal removal of a given drug, are molecular weight, protein binding, and distribution volume. In many cases, the extracorporeal removal of antimicrobials can be relevant, with a consistent risk of underdosing-related treatment failure and/or potential onset of bacterial resistance. It should also be taken into account that renal replacement therapies are often not standardized in critically ill patients, and their impact on plasma drug concentrations may substantially vary in relation to membrane characteristics, treatment modality, and delivered dialysis dose. Thus, in this clinical scenario, the knowledge of the pharmacokinetic and pharmacodynamic properties of different antimicrobial classes is crucial to tailor maintenance dose and/or time interval according to clinical needs. Finally, especially for antimicrobials known for a tight therapeutic range, therapeutic drug monitoring is strongly suggested to guide dosing adjustment in complex clinical settings, such as septic patients with acute kidney injury undergoing renal replacement therapy.

摘要

在伴有急性肾损伤的危重症患者中,对抗菌药物进行精细化管理至关重要,尤其是需要肾脏替代治疗的患者。急性肾损伤可能导致药物药代动力学参数发生具有临床意义的改变,而需要肾脏替代治疗则是另一个需要考虑的变量,以避免不恰当的抗菌治疗。最重要的药代动力学参数,有助于确定某种药物体外清除的重要性,包括分子量、蛋白结合率和分布容积。在许多情况下,抗菌药物的体外清除可能具有重要意义,存在与剂量不足相关的治疗失败和/或潜在细菌耐药风险。还应考虑到,危重症患者的肾脏替代治疗通常不规范,其对血浆药物浓度的影响可能因膜特性、治疗方式和给予的透析剂量而有很大差异。因此,在这种临床情况下,了解不同抗菌药物类别的药代动力学和药效动力学特性对于根据临床需求调整维持剂量和/或间隔时间至关重要。最后,特别是对于治疗窗较窄的抗菌药物,强烈建议进行治疗药物监测以指导在复杂临床情况下(例如伴有急性肾损伤的脓毒症患者进行肾脏替代治疗)进行剂量调整。

相似文献

引用本文的文献

2

本文引用的文献

5
Population pharmacokinetics of daptomycin in critically ill patients.重症患者中达托霉素的群体药代动力学。
Int J Antimicrob Agents. 2018 Aug;52(2):158-165. doi: 10.1016/j.ijantimicag.2018.03.008. Epub 2018 Mar 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验